The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The effect of curcumin supplementation on clinical outcomes and inflammatory markers in patients with ulcerative colitis
Abstract
Background and aims: Curcumin has anti‐inflammatory properties. The aim of this study was to evaluate the effect of curcumin on improvement of the disease activity in ulcerative colitis (UC). Methods: In this randomized double‐blind clinical trial, 70 patients with mild‐to‐moderate UC were randomly assigned to curcumin (1,500 mg/day) or placebo intake for 8 weeks. Disease clinical activity, quality of life, serum levels of tumor necrosis factor alpha (TNF‐α), high‐sensitivity C‐reactive protein (hs‐CRP), erythrocyte sedimentation rate (ESR) values, and complete blood count were measured. Results: Changes in Simple Clinical Colitis Activity Index score were significantly higher in the curcumin than the placebo group (–5.9 ± 2.08 vs. –2.1 ± 2.6; p = .001). The scores of Inflammatory Bowel Disease Questionnaire‐9 and quality of life were significantly higher in the intervention group compared to the control group ( p = .006). Furthermore, the curcumin supplementation reduced the serum hs‐CRP concentration (–6.3 ± 13.6 vs. 3.7 ± 11.6 μg/ml; p = .01) and ESR levels significantly (–1.6 ± 2.7 vs. –0.09 ± 2.4 mm/hr; p = .02) in comparison with the control group. No significant changes were observed in the TNF‐α levels of both groups. Conclusions: Consumption of the curcumin supplement, along with drug therapy, is associated with significant improvement of the clinical outcomes, quality of life, hs‐CRP, and ESR in patients with mild‐to‐moderate UC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“although significant findings were only reported in studies that evaluated either curcumin extract administered orally at doses ≥1000 mg/ day (Lang et al., 2015;Sadeghi et al., 2019) or bio-enhanced curcumin at doses <1000 mg/day (Banerjee et al., 2021;Masoodi et al., 2018;Sugimoto et al., 2020).”
From A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders (2024) · cites this paper as Sadeghi et al., 2019
In the citing paper
“In another study, mean IBDQ scores at 24 weeks of treatment were not significantly different between curcumin and placebo groups (curcumin: 178.5 ± 25.8 vs. placebo: 181.5 ± 24.7; p = 0.80) (Sadeghi et al., 2019).”
From A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders (2024) · cites this paper as Sadeghi et al., 2019
In the citing paper
“For curcumin extract at 1500 mg/day, the change from baseline to 8 weeks in mean IBDQ-9 scores for the curcumin group did not differ significantly from that of the placebo group, after adjusting for differences in baseline values ( p = 0.08) (Sadeghi et al., 2019).”
From A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders (2024) · cites this paper as Sadeghi et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Epidemiology and risk factors for IBD
Ananthakrishnan, A. N. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.34 · Cited by 1,741
Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B
Wahl, C., Liptay, S., Adler, G., & Schmid, R. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci992 · Cited by 742
Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis
Higgins, P. D. R., Schwartz, M., Mapili, J., Krokos, I., Leung, J., & Zimmermann, E. M. (2005) · Gut · doi:10.1136/gut.2004.056358 · Cited by 244
Research works printed but not linked: 38
- 10.1249/01.MSS.0000074446.02192.14 · DOI
- 10.1002/ptr.6328 · DOI
- 10.1089/jmf.2017.3930 · DOI
- 10.1016/j.fct.2009.03.003 · DOI
- 10.1111/j.1572-0241.2004.04071.x · DOI
- 10.1023/A:1020841601110 · DOI
- 10.3748/wjg.v20.i28.9458 · DOI
- 10.1038/ajg.2015.194 · DOI
- 10.1097/00006842-199111000-00010 · DOI
- Gholamrezaei A., 2011, Linguistic validation of the Inflammatory Bowel Disease Questionnaire‐Short Form (IBDQ‐9) in Iranian population, Journal of Isfahan Medical School, 28
- 10.1016/j.cgh.2006.08.008 · DOI · Paper page
- 10.1111/j.1572-0241.2005.40641.x · DOI
- 10.1007/BF02231364 · DOI
- 10.1007/s10620-005-3032-8 · DOI
- 10.3748/wjg.v11.i12.1747 · DOI
- 10.4049/jimmunol.163.6.3474 · DOI
- 10.1080/00365520310000654 · DOI
- 10.4292/wjgpt.v8.i2.147 · DOI · Paper page
- 10.1016/j.cgh.2015.02.019 · DOI · Paper page
- 10.1016/j.intimp.2013.06.020 · DOI
- 10.1002/jcb.27273 · DOI · Paper page
- 10.1016/j.crohns.2012.07.012 · DOI
- 10.1007/s12328-016-0686-z · DOI
- 10.1038/nri3661 · DOI · Paper page
- 10.1111/j.1440-1746.2008.05413.x · DOI
- Öztürk Z., 2013, Could platelet indices be new biomarkers for inflammatory bowel diseases, European Review for Medical and Pharmacological Sciences, 17, 334
- 10.3390/molecules191220091 · DOI · Paper page
- 10.1016/j.phrs.2016.03.026 · DOI
- 10.1111/j.1365-2036.2005.02380.x · DOI
- 10.1177/0091270007301623 · DOI
- 10.1007/s00394-011-0188-1 · DOI · Paper page
- 10.1016/j.crohns.2013.08.006 · DOI
- 10.1016/j.drudis.2016.03.007 · DOI
- Su H. J., 2018, Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates, Journal of the Formosan Medical Association
- 10.1038/sj.bjp.0705241 · DOI
- 10.1016/S0140-6736(16)32126-2 · DOI
- 10.1080/09537100902856781 · DOI
- 10.1159/000094531 · DOI
Cited by
A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders
Thavorn, K., Wolfe, D., Faust, L., Shorr, R., Akkawi, M., Isaranuwatchai, W., Klinger, C., Chai‐Adisaksopa, C., Tanvejsilp, P., Nochaiwong, S., et al. (2024) · Phytotherapy Research · doi:10.1002/ptr.8189 · Cited by 11
Metadata
- Authors
- Sadeghi, N., Mansoori, A., Shayesteh, A., & Hashemi, S. J.
- Affiliations
- Nutrition and Metabolic Diseases Research Center Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran
- Alimentary Tract Research Center Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran
- Venue
- Phytotherapy Research
- Publisher
- Wiley
- Published
- 2019-12-04
- Volume
- 34
- Issue
- 5
- Pages
- 1123-1133
- ISSN
- 0951-418X
- 1099-1573
- Cited by
- 132
- References
- 4
- Language
- en
- Funders
- Ahvaz Jundishapur University of Medical Sciences (NRC‐9626)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
